[{"id":"ffa36ee9-c0da-420e-bc20-b503b2b0b217","acronym":"TBCRC 058","url":"https://clinicaltrials.gov/study/NCT06099769","created_at":"2023-10-25T19:14:04.278Z","updated_at":"2025-02-25T15:36:36.074Z","phase":"Phase 2","brief_title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","source_id_and_acronym":"NCT06099769 - TBCRC 058","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PD-L1 • AR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • AR positive","tags":["HER-2 • PD-L1 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)"],"overall_status":"Recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-20"},{"id":"50be0dbf-09bd-4202-b9dc-9320f03f560b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02788981","created_at":"2021-01-18T13:40:57.897Z","updated_at":"2024-07-02T16:35:19.046Z","phase":"Phase 2","brief_title":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02788981","lead_sponsor":"University of Chicago","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Korlym (mifepristone)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/28/2017","start_date":" 03/28/2017","primary_txt":" Primary completion: 12/21/2022","primary_completion_date":" 12/21/2022","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-02-16"},{"id":"c5f64fa9-138b-4dfe-a9fb-1c488c2cbb7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02014337","created_at":"2021-01-18T09:12:42.369Z","updated_at":"2024-07-02T16:37:14.764Z","phase":"Phase 1","brief_title":"Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors","source_id_and_acronym":"NCT02014337","lead_sponsor":"Corcept Therapeutics","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Korlym (mifepristone)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-01-17"}]